UK and Eli Lilly launch £85 million obesity care program
An £85 million UK partnership will test AI triage and virtual advice as routes into obesity care, another attempt to reach patients outside traditional clinic visits.
The UK government and Eli Lilly launched an £85 million program on 29 June 2026 to widen access to obesity care, split between £50 million in government funding and £35 million from Lilly, the maker of the weight-loss drug Mounjaro (tirzepatide) [1].
The Obesity Pathway Innovation Programme (OPIP) will fund a dozen projects in what the Department of Health and Social Care (DHSC) calls underserved communities around the UK [1]. A stated aim is to ease pressure on frontline health services "by using technology to give people new ways to access support" [1].
The largest example is an AI-assisted triage pilot in Norfolk, Suffolk and northeast Essex. People worried about their weight would fill out an online health check at home instead of booking an appointment with a GP, the general-practitioner doctors who serve as the first point of contact in the NHS. Depending on the result, they could be offered NHS support such as dietitian advice or specialist clinical care [1].
A separate Kent pilot will deliver advice by WhatsApp on healthy eating, activity, sleep and stress during pregnancy and a child's early years [1]. In Leicester and Northamptonshire, weight management support will run through local hubs [1]. The DHSC said the program is meant to reach people in deprived rural and coastal communities who often travel long distances for in-person care, minority ethnic communities, people with disabilities and early years families [1].
Some of the projects aim to improve access to weight-loss medication "where clinically appropriate," according to the DHSC [1]. Which medicines would be involved, how many patients might receive them and how people would be selected has not been reported. The £85 million funds the projects themselves, not the drugs [1].
"What we learn from these projects has the potential to help people across the country live healthier lives," Health Secretary James Murray said, adding that it supports the government's 10-Year Health Plan and a shift "from treatment to prevention" [1]. Chris Stokes, president and general manager of Lilly UK and Northern Europe, said, "Obesity is a significant health challenge for the UK" and that Lilly is "proud to work with the government to support NHS partners" [1].
The announcement came a week after Lilly launched LillyDirect in the UK, a post-prescription dispensing and delivery service that operates through a network of private, UK-regulated health care organizations [1]. Lilly is also the maker of Zepbound and Mounjaro, both tirzepatide; semaglutide is sold as Ozempic, Wegovy and Rybelsus by Novo Nordisk, which is not named in this program [1].
About a third of adults in England are living with obesity, according to a study published the week before the announcement, with rates rising fastest in young adults [1]. Estimates put the cost to UK society at up to £107 billion a year, including more than £9 billion a year for the NHS [1].
Why it matters for patients
This is a British program funded through the NHS, so it does not change insurance coverage, pricing or availability of GLP-1 medications in the United States. What it does show is the direction some governments and drugmakers are testing: using online screening, AI triage and messaging apps to decide who gets weight-related care and how they get it, rather than routing everyone through an in-person doctor visit first [1].
For US patients, the practical question is whether tools like these spread. If a health system or insurer adopts similar triage, patients might be directed toward dietitian advice, digital coaching or a local hub before, or instead of, a prescription — a step that could speed access for some people and add a step for others. The UK announcement does not say how patients would be prioritized for medication or whether a clinician would still review each case, and those details have not been disclosed [1].
What happens next
The program is funded and the projects are planned, but the announcement gave no start dates, no enrollment figures and no timeline for when results would be published [1]. It also did not say how the AI triage pilot in Norfolk, Suffolk and northeast Essex would be evaluated, or what would happen to patients it flags [1]. LillyDirect, launched the week before, is already operating as a delivery service for private prescriptions in the UK [1].
Images from the sources
Sources
Semaglutides.org provides information only, not medical advice. Talk to a licensed provider about your own care before making changes. Some telehealth links are affiliate links and are labeled where they appear.